The company is working on a brain implant designed to assist individuals with severe paralysis in controlling external technologies solely through neural signals. Neuralink initiated the recruitment of patients for its inaugural in-human clinical trial in the fall, following the approval granted by the U.S. Food and Drug Administration in May to conduct the study.